By the end of 2024, the total number of medical and health institutions nationwide reached 1,093,551, an increase of 22,766 compared to the previous year.

Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

By 2030, a diabetes prevention and treatment system will enable over 60% of residents aged 18 and above to be aware of the disease. By then, the coverage rate of standardized management services for type 2 diabetes patients at the primary level will exceed 70%, according to the documents released by multiple departments including the National Health Commission (NHC).

Eli Lilly has opened a new R&D facility in the Boston Seaport district with the aim of advancing the firm's RNA and DNA-based therapies, as well as discovering new drug targets and developing new medicines.

Illumina, Inc. (NASDAQ: ILMN) today is hosting a Strategy Update for investors to present its strategy and three-year financial outlook that features accelerating revenue growth and significant margin expansion.

In terms of the market share, the biochemical industry in the international market is highly concentrated. The “four giants” (Roche, Beckman, Siemens, and Abbott) have occupied more than 80% of the market share in the international market by virtue of their first-mover advantage. Domestically, many companies enter the IVD field due to low market entry barrier and high gross profit margins of biochemical reagents, so there are numerous enterprises.

Quanterix on Thursday reported an 11 percent rise in second quarter 2024 revenues.

A new study conducted by Quest Diagnostics in collaboration with the University of Alabama has revealed significant gaps in the testing and treatment of sexually transmitted infections (STIs) among pregnant women in the United States.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Paige, a global leader in clinical AI applications for cancer, in collaboration with Microsoft, has unveiled the second generation of Virchow, its million-slide foundation model for cancer. As additions to Paige’s suite of foundation models, the world’s largest and most advanced AI models in clinical pathology, Virchow2 and Virchow2G offer a deeper understanding of cells and tissue, aiming to redefine cancer diagnosis and treatment.

Missouri-based diagnostic provider C2N has struck a deal with diagnostic services provider Unilabs to expand access to its Precivity portfolio of Alzheimer’s blood tests in over 75 countries.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2024.